


**IN THE CLAIMS:**

1. (Withdrawn) A serotonin reuptake inhibitor comprising:
  - a first part, wherein the first part comprises a moiety with antidepressant properties and having an affinity for the serotonin reuptake transporter (SERT); and
  - a second part, wherein the second part comprises a moiety having an affinity to serotonin (5-HT) receptors, and wherein the second part is coupled to the first part.
2. (Withdrawn) The serotonin reuptake inhibitor of claim 1, wherein the 5-HT is 5-HT<sub>1A</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>2C</sub>, or 5-HT<sub>3</sub>.
3. (Withdrawn) The serotonin reuptake inhibitor of claim 1, wherein the 5-HT is 5-HT<sub>2A</sub>.
4. (Cancelled)
5. (Withdrawn) A serotonin reuptake inhibitor comprising a bi-functional organic molecule combining serotonin (5-HT) receptor antagonism and serotonin reuptake inhibition into one molecular entity.
6. (Withdrawn) The serotonin reuptake inhibitor of claim 5, wherein the 5-HT is 5-HT<sub>1A</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>2C</sub>, or 5-HT<sub>3</sub>.
7. (Withdrawn) The serotonin reuptake inhibitor of claim 5, wherein the 5-HT is 5-HT<sub>2A</sub>.
8. (Withdrawn) A serotonin reuptake inhibitor comprising a structural homologue of an antidepressant serotonin-selective reuptake inhibitor (SSRI) capable of inhibiting serotonin reuptake transporter (SERT) coupled to a piperazine or piperidine moiety being antagonistic to a serotonin (5-HT) receptor.
9. (Withdrawn) The serotonin reuptake inhibitor of claim 8, wherein the 5-HT is 5-HT<sub>1A</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>2C</sub>, or 5-HT<sub>3</sub>.

10. (Withdrawn) The serotonin reuptake inhibitor of claim 8, wherein the 5-HT is 5-HT<sub>2A</sub>.


11. (Currently Amended) A serotonin reuptake inhibitor compound having the general formula:



wherein X is F; and




salt thereof.

12. (Currently Amended) A serotonin reuptake inhibitor compound having the general formula:




wherein X is F;

wherein NR<sub>1</sub>R<sub>2</sub> is:



, or





















; and


salt thereof.

13. (Cancelled)

14. (Currently Amended) A ~~serotonin reuptake inhibitor~~ compound having the formula:







15. (Withdrawn) A method for treating depression in a patient, comprising:  
administering the serotonin reuptake inhibitor of claim 1.

16. (Withdrawn) A method for treating depression in a patient, comprising:  
administering the serotonin reuptake inhibitor of claim 4.

17. (Withdrawn) A method for treating depression in a patient, comprising:  
administering the serotonin reuptake inhibitor of claim 5.

18. (Withdrawn) A method for treating depression in a patient, comprising:  
administering the serotonin reuptake inhibitor of claim 8.

19. (Withdrawn) A method for treating depression in a patient, comprising:  
administering the serotonin reuptake inhibitor of claim 12.

20. (Withdrawn) A pharmaceutical formulation for the treatment of depression in a patient,  
comprising:  
a pharmaceutically effective amount of the serotonin reuptake inhibitor of claim 1.

21. (Cancelled)

22. (Withdrawn) A pharmaceutical formulation for the treatment of depression in a patient, comprising:

a pharmaceutically effective amount of the serotonin reuptake inhibitor of claim 5.

23. (Withdrawn) A pharmaceutical formulation for the treatment of depression in a patient, comprising:

a pharmaceutically effective amount of the serotonin reuptake inhibitor of claim 8.

24. (Currently Amended) A pharmaceutical formulation compound for the treatment of depression in a patient, comprising:

a pharmaceutically effective amount of the serotonin reuptake inhibitor of claim 12.